ey0020.8-1 | Clinical Trials – New Treatments | ESPEYB20
GP Forlenza
, J McVean
, RW Beck
, C Bauza
, R Bailey
, B Buckingham
, LA DiMeglio
, JL Sherr
, M Clements
, A Neyman
, C Evans-Molina
, EK Sims
, LH Messer
, L Ekhlaspour
, R McDonough
, M Van Name
, D Rojas
, S Beasley
, S DuBose
, C Kollman
, A Moran
, CLVer Study Group
Brief summary: In this double-blind, randomized clinical trial conducted in 6 US centres, 88 children and adolescents (aged 717 years) with newly diagnosed type 1 diabetes (T1D) were randomized to either once-daily oral verapamil or placebo, within 1 month from diagnosis. Treatment with verapamil led to better stimulated C-peptide secretion at 52 weeks post-diagnosis, with levels 30% higher compared to placebo.Verapamil is a calcium channel blocker...